obatoclax: Clinical Trials

19 trials of obatoclax, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 6 terminated, 2 withdrawn. 13 Phase 2, 12 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Completed 9, Terminated 3, Withdrawn 1
Phase 112Completed 6, Terminated 5, Withdrawn 1
Phase 31Withdrawn 1

Follow obatoclax: new trials by email Literature Review of obatoclax trials Research Report on obatoclax

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of Obatoclax Mesylate in Combination With Carboplatin and Etoposide Compared With Carboplatin and Etoposide Alone in Chemotherapy-Naive Patients With Extensive-Stage Small Cell Lung Cancer
Obatoclax Mesylate, Carboplatine and Etoposide, Carboplatin and Etoposide - Extensive-stage Small Cell Lung Cancer
Phase 3WithdrawnCephalon2012-08-012012-08-15
Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
bendamustine hydrochloride, obatoclax mesylate, rituximab - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Phase 1 / Phase 2WithdrawnNational Cancer Institute (NCI)2010-10-012013-06-06
Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia
dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)222009-06-012014-05-01
Obatoclax for Systemic Mastocytosis
Obatoclax Mesylate - Leukemia, Systemic Mastocytosis
Phase 2TerminatedM.D. Anderson Cancer Center32009-06-012011-11-04
Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
obatoclax mesylate, bortezomib, laboratory biomarker analysis - Refractory Multiple Myeloma, Stage I Multiple Myeloma
Phase 1 / Phase 2TerminatedNational Cancer Institute (NCI)112008-07-012015-01-12
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Obatoclax Mesylate, Temozolomide - Metastatic Melanoma
Phase 1 / Phase 2TerminatedGemin X12008-06-012016-07-22
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Obatoclax, Carboplatin/etoposide - Extensive-stage Small Cell Lung Cancer
Phase 1 / Phase 2CompletedGemin X2182008-05-012016-07-21
Study of Obatoclax in Previously Untreated Acute Myeloid Leukemia (AML)
Obatoclax - AML
Phase 2CompletedGemin X182008-04-012013-08-26
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
obatoclax mesylate, fludarabine phosphate, rituximab - B-cell Chronic Lymphocytic Leukemia, Leukemia
Phase 1TerminatedNational Cancer Institute (NCI)282008-01-012013-09-30
Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma
obatoclax mesylate, bortezomib, laboratory biomarker analysis - Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
Phase 1TerminatedNational Cancer Institute (NCI)182007-12-012015-12-04
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis - Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)222007-08-012015-05-05
Safety and Efficacy of Single Agent Obatoclax Mesylate (GX15-070MS) Followed by a Combination With Rituximab for Previously-untreated Follicular Lymphoma (FL)
Obatoclax mesylate, Rituximab - Lymphoma, Follicular
Phase 2CompletedGemin X72007-03-012016-07-22
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)for the Treatment of Myelodysplastic Syndromes (MDS)
Obatoclax mesylate (GX15-070MS) - Myelodysplastic Syndromes
Phase 2CompletedGemin X242006-12-012013-08-26
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Obatoclax mesylate 250 ml, Docetaxel - Lung Cancer
Phase 1 / Phase 2CompletedGemin X472006-10-012016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Obatoclax mesylate, Bortezomib - Mantle-Cell Lymphoma
Phase 1 / Phase 2CompletedGemin X242006-10-012016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
Obatoclax mesylate (GX15-070MS) - Myelofibrosis
Phase 2CompletedGemin X222006-07-012013-08-26
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma
Obatoclax mesylate (GX15-070MS) - Hodgkin's Lymphoma
Phase 2CompletedGemin X132006-07-012012-08-06
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
Obatoclax mesylate (GX15-070MS) - Hematological Malignancies
Phase 1CompletedGemin X442005-10-012014-05-12
A Phase I/II Study of GX15-070MS in Untreated CLL
GX15-070MS - Chronic Lymphocytic Leukemia
Phase 1CompletedGemin X262004-09-012014-05-12

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (4)  ·  Lymphoma, Follicular (3)  ·  Lymphoma, Mantle-Cell (3)  ·  Small Cell Lung Carcinoma (3)  ·  Leukemia (2)  ·  Lymphoma, B-Cell, Marginal Zone (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Blast Crisis (1)  ·  Burkitt Lymphoma (1)  ·  Dendritic Cell Sarcoma, Interdigitating (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Intraocular Lymphoma (1)  ·  Leukemia, Biphenotypic, Acute (1)

Sponsors

Gemin X (11)  ·  National Cancer Institute (NCI) (6)  ·  Cephalon (1)  ·  M.D. Anderson Cancer Center (1)

Countries

United States (18)  ·  Canada (7)  ·  Bulgaria (1)  ·  Czechia (1)  ·  Hungary (1)  ·  India (1)  ·  Poland (1)  ·  Romania (1)  ·  Serbia (1)  ·  United Kingdom (1)

Top investigators

Jean Viallet, MD (9)  ·  Mark Berger, MD (2)  ·  Alexander Stewart (1)  ·  Elizabeth Christian (1)  ·  Jennifer Brown (1)  ·  Joseph Tuscano (1)  ·  Lee Krug (1)  ·  Richard Aplenc (1)  ·  Srdan Verstovsek, MD (1)

Results publications

PMID 18931344, PMID 19088047, PMID 20709666, PMID 21620511, PMID 22383790, PMID 23393050, PMID 24997137, PMID 25052051, PMID 25285531

NIH funding

N01CM62203 (1), N01CM62205 (1), N01CM62208 (1), U01CA062490 (1), U01CA062505 (1), U01CA076576 (1), U01CA097452 (1)